is trailing the S&P 500
over the past 12 months, up 27% while the broader index is up 38%. FibroGen
(ticker: ACAD) down 51% so far in 2021, (FGEN) down 33%, and
Acadia Pharmaceuticals This year has been marked by some stunning disappointments for healthcare investors, with
(SRPT) down 50%. Sarepta Therapeutics
We ran that screen this week, and came up with the five healthcare names in the S&P 500 trading the farthest below their average analyst price targets. The five companies are a solid group of stocks that have had rocky go of it in the market but appear to be undervalued. The stocks are So where should investors look for value? One strategy is to look to Wall Street analysts, who set target prices on the stocks they cover, and to pick companies trading the farthest below those projected price points.
News Highlights Health
- 5 undervalued health stocks | Barron
- Check all news and articles from the Health news information updates.